Recent activity includes its global licensing agreement with Chinas 3SBio in 2025 for cancer drug candidate SSGJ-707, worth $1.25 billion upfront and up to $4.8 billion in milestones, as well as a 2025 GLP-1 collaboration with YaoPharma
doi: 10.1038/s41591-024-02996-7 Summary Keywords semaglutide, arrhythmic, cardiovascular, microvascular, type 2 diabetes, meta-analysis Citation Wu R, Xing B, Huang Y, Zhou Z, Sun B, Yu L and Wang H (2025) Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis
How much does medical weight management cost at Craft Concierge
Increased Risk of Contamination: When exposed to higher temperatures, the risk of microbial growth increases, which can pose health risks if the medication is consumed
The ratio between VmaxPox5/ VmaxAckA is 1.43 0.9
Why should I trust my acne scar treatment to Access Medspa Rejuvenate
